10-KPeriod: FY2018

PFIZER INC Annual Report, Year Ended Dec 31, 2018

Filed February 28, 2019For Securities:PFE

Summary

Pfizer Inc.'s 2018 10-K filing highlights a year of strategic transformation and ongoing business development. A significant event for investors is the announced agreement to combine its consumer healthcare business with GSK's, forming a joint venture where Pfizer will hold a 32% equity stake. This move signals a strategic pivot, shifting focus towards its biopharmaceutical core. The company operated under a dual-segment structure (Innovative Health and Essential Health) throughout 2018, but is transitioning to a new three-business global structure (Biopharmaceuticals Group, Upjohn, and Consumer Healthcare) starting in 2019. This reorganization aims to capitalize on evolving market dynamics and drive future growth. Key operational areas include the biopharmaceutical group, focusing on novel medicines and vaccines across critical therapeutic areas like oncology, inflammation & immunology, and rare diseases, alongside a new hospital business unit. The Upjohn segment addresses off-patent established medicines, primarily in China. The filing also details significant R&D efforts and a robust pipeline, though it acknowledges the inherent risks and costs associated with drug development and the competitive landscape. Investors should note the company's significant international revenue contribution, which exposes it to currency fluctuations and varying regulatory environments.

Financial Highlights

56 data points
Beta

Revenue

$40.83B

78.0% Gross Margin

Net Income

$11.15B

27.3% Net Margin

EPS (Diluted)

$1.87

Total Assets

$159.42B

Cash & Equivalents

$1.14B

Free Cash Flow

$13.84B

Financial Statements
Beta
Revenue$40.83B
Cost of Revenue$8.99B
Gross Profit$31.84B
SG&A Expenses$12.61B
Operating Income$3.83B
Interest Expense$1.32B
Net Income$11.15B
EPS (Basic)$1.90
EPS (Diluted)$1.87
Shares Outstanding (Basic)5.87B
Shares Outstanding (Diluted)5.98B

Key Highlights

  • 1Pfizer announced an agreement to combine its consumer healthcare business with GSK's into a new global joint venture, with Pfizer retaining a 32% equity stake.
  • 2The company is reorganizing its commercial operations into three distinct businesses effective 2019: Pfizer Biopharmaceuticals Group, Upjohn, and Consumer Healthcare.
  • 3Pfizer's business segments for 2018 were Pfizer Innovative Health (IH) and Pfizer Essential Health (EH), with IH focusing on novel therapies and EH on established, off-patent medicines.
  • 4Significant investments in Research and Development (R&D) are noted, with a focus on therapeutic areas like Oncology, Inflammation & Immunology, Rare Diseases, and Vaccines.
  • 5International operations are a substantial part of Pfizer's business, accounting for 53% of total revenues in 2018, highlighting exposure to global economic and regulatory factors.
  • 6The company actively engages in business development, including alliances, licenses, joint ventures, and acquisitions, to drive growth and enhance shareholder value.
  • 7Patent expirations and the increasing threat of generic and biosimilar competition are identified as key risks impacting revenue for several major products.

Frequently Asked Questions

The most significant strategic shift announced is the agreement to combine Pfizer's consumer healthcare business with GSK's into a joint venture. This move suggests a strategic focus on core biopharmaceutical operations, while divesting from consumer health. Furthermore, Pfizer is reorganizing its commercial structure into three global businesses (Biopharmaceuticals Group, Upjohn, and Consumer Healthcare) starting in 2019, indicating an effort to align operations with specific market dynamics and growth opportunities.

For 2018, Pfizer operated under two segments: Innovative Health (IH), focusing on novel medicines and vaccines in areas like internal medicine, oncology, inflammation & immunology, rare disease, and consumer healthcare; and Essential Health (EH), which included established, off-patent products such as Lipitor, Norvasc, and Lyrica (in certain regions), as well as sterile injectables and biosimilars. Post-2019, the structure shifts to Biopharmaceuticals Group, Upjohn (off-patent established medicines), and Consumer Healthcare.

Key risks include the increasing competition from generic and biosimilar drugs, particularly as patents for major products expire (e.g., Lyrica in the US is nearing patent expiration). Other significant risks involve managed care trends and pricing pressures from payers, government regulations and pricing constraints both domestically and internationally, and potential disruptions in product manufacturing and supply chains. The company also faces risks related to its R&D investments, as drug development is expensive and uncertain, and the success of its strategic transactions, like the GSK joint venture, is subject to approvals and integration challenges.

International operations are a substantial contributor to Pfizer's revenue, accounting for 53% of its total revenues in 2018. This broad global presence exposes Pfizer to various risks, including currency fluctuations, different regulatory environments and pricing controls in various countries, political and economic instability in emerging markets, and challenges related to intellectual property protection.